Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCI-024 and BCI-049 in Major Depressive Disorder
NCT00705003Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- May 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of buspirone and melatonin in major depressive disorder (MDD) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Clinical Global Impression-Improvement at 6 weeks. Started May 2008; status: completed.
02
Drugs
buspironemelatonin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00705003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705003.